NOCOPI ANNOUNCES EUROPEAN AGREEMENT
NOCOPI ANNOUNCES EUROPEAN AGREEMENT WAYNE, Pa., April 24 /PRNewswire/ -- Nocopi International, Inc.
(OTC Bulletin Board: NOOP) and Applied Holographics Plc. of London, today announced that they had entered into a marketing agreement for Nocopi's reactive imaging technology for the United Kingdom and Ireland.
The announcement was made by Dr. David Tidmarsh, managing director and chief executive officer of Applied Holographics, and Norman A. Gardner, president and chief executive officer of Nocopi. Applied Holographics is Europe's leading hologram company and is a world innovator in the research and development of commercial holography. The company supplies holograms to major security printers throughout the United Kingdom and Europe. Its best known security hologram, that of William Shakespeare, currently is in use by the Association for Payment Clearing Services which represents the major clearing banks in the United Kingdom. Glaxo Laboratories Ltd. was the first pharmaceutical company in the United Kingdom to use holograms which were supplied by Applied Holographics to protect its leading medicine, Zantac, against drug counterfeits. "Counterfeiting is one of the world's fastest-growing crimes," said Tidmarsh. "We view the addition of the Nocopi product line to our core hologram business as an immense advantage in dealing with this growing problem. The Nocopi technology is an ideal complement to our hologram product." Nocopi International, Inc., based in Wayne, is a publicly traded U.S. corporation which owns a patented technology to prevent photocopying and faxing of confidential information as well as a system to verify the originality of documents and products. /delval/ -0- 4/24/92 /CONTACT: Norman A. Gardner, president and chief executive officer of Nocopi International, 800-662-6741, or 215-687-2000/ (NOOP) CO: Nocopi International, Inc.; Applied Holographics Plc. ST: Pennsylvania IN: SU: CON
MP-MK -- PH006 -- 2309 04/24/92 09:23 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Apr 24, 1992|
|Previous Article:||POTENTIAL NEW CANCER THERAPEUTIC DEVELOPED BY IMMUNOMEDICS AND NATIONAL CANCER INSTITUTE TEAM; RESULTS PRESENTED AT CANCER MEETING|
|Next Article:||DONNELLY CORPORATION ANNOUNCES DIVIDEND|